

## REFERENCES



Abboud, RT. and Sanders, HD. (1976). Effect of oral administration of deltatetrahydrocannabinol on airway mechanics in normal and asthmatic subjects. *Chest*, **70**, 480-5.

Abbracchio, MP., Burnstock, G., Boeynaems, JM., Barnard, EA., Boyer, JL., Kennedy, C., Knight, GE., Fumagalli, M., Gachet, C., Jacobson, KA. and Weisman, GA. (2006). International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. *Pharmacol Rev*, **58**, 281-341.

Abrams, DI., Vizoso, HP., Shade, SB., Jay, C., Kelly, ME. and Benowitz, NL. (2007). Vaporization as a smokeless cannabis delivery system: a pilot study. *Clin Pharmacol Ther*, **82**, 572-8.

Ackerman, NR. (1977). The lack of an effect of  $\Delta^9$ -THC on pulmonary smooth muscle function in guinea-pig. *Toxicol Appl Pharmacol*, **41**, 321-8.

Agopyan, N., Bhatti, T., Yu, S. and Simon, SA. (2003). Vanilloid receptor activation by 2- and 10- $\mu$ m particles induces responses leading to apoptosis in human airway epithelial cells. *Toxicol Appl Pharmacol*, **192**, 21-35.

Aldington, S., Williams, M., Nowitz, M., Weatherall, M., Pritchard, A., McNaughton, A., Robinson, G. and Beasley, R. (2007). Effects of cannabis on pulmonary structure, function and symptoms. *Thorax*, **62**, 1058-63.

Alton, EW., Kingsleigh-Smith, DJ., Munkonge, FM., Smith, SN., Lindsay, AR., Gruenert, DC., Jeffery, PK., Norris, A., Geddes, DM and Williams, AJ. (1996). Asthma prophylaxis agents alter the function of an airway epithelial chloride channel. *Am J Respir Cell Mol Biol*, **14**, 380-7.

Andersson, DA., Adner, M., Högestätt, ED. and Zygmunt, PM. (2002). Mechanism underlying tissue selectivity of anandamide and other vanilloid receptor agonists. *Mol Pharmacol*, **62**, 705-13.

Antonissen, LA., Mitchell, RW., Kroeger, EA., Kepron, W., Stephens, NL. and Bergen, J. (1980). Histamine pharmacology in airway smooth muscle from a canine model of asthma. *J Pharmacol Exp Ther*, **213**, 150-5.

Ashton, JC. (2007). Cannabinoids for the treatment of inflammation. *Curr Opin Pharmacol*, **8**, 373-84.

Austen, KF. and Boyce, JA. (2001). Mast cell lineage development and phenotypic regulation. *Leu Res*, **25**, 511-8.

Baczynsky, WO. and Zimmerman, AM. (1983). Effects of  $\Delta^9$ -tetrahydrocannabinol, cannabiniol and cannabidiol on the immune system in mice. *Pharmacology*, **26**, 12-9.

- Bachelet, I. and Levi-Schaffer, F. (2007). Mast cells as effector cells: a co-stimulating question. *Trends Immunol*, **28**, 360-5.
- Bahra, P., Mesher, J., Li, S., Poll, CT. and Danahay, H. (2004). P2Y<sub>2</sub>-receptor mediated activation of a contralateral, lanthanide-sensitive calcium entry pathway in the human airway epithelium. *Br J Pharmacol*, **143**, 91-8.
- Baker, D., Pryce, G., Davies, WL. and Hiley, RC. (2006). *In silico* patent searching reveals a new cannabinoid receptor. *Trends Pharmacol Sci*, **27**, 1-4.
- Baker, D., Pryce, G., Giovannoni, G. and Thompson, AJ. (2003). The therapeutic potential of cannabis. *The Lancet Neurology*, **2**, 291-8.
- Baraldo, S., Oliani, KL., Turato, G., Zuin, R. and Saetta, M. (2007). The role of lymphocytes in the pathogenesis of asthma and COPD. *Curr Med Chem*, **14**, 2250-6.
- Barnes, D. (1985). Hormonally defined, serum-free media for epithelial cells in culture. In: Taub, M. (Ed.), *Tissue culture of epithelial cells*. Plenum Press, New York, 235-53.
- Barnes, PJ. (1986). Neural control of human airways in health and disease. *Am Rev Respir Dis*, **134**, 1289-314.
- Barnes, PJ. (1996a). Neuroeffector mechanisms: the interface between inflammation and neuronal responses. *J Allergy Clin Immunol*, **98**, S73-83.
- Barnes, PJ. (1996b). Pathophysiology of asthma. *Br J Clin Pharmacol*, **42**, 3-10.
- Barnes, PJ. (1996c). What is the role of nerves in chronic asthma and symptoms? *Am J Resp Crit Care Med*, **153**, S5-8.
- Barnes, PJ. (1999). Airway muscarinic receptors. In: Spector, S.L. (Ed.), *Anticholinergic agents in the upper and lower airways*. Marcel Dekker, New York, Basel, 31-58.
- Barnes, PJ. (2000). Drugs for asthma. *Br J Pharmacol*, **147**, S297-303.
- Barnes, PJ. (2001). Neurogenic inflammation in the airways. *Respir Physiol*, **125**, 145-54.
- Barnes, PJ. (2006a). Against the Dutch hypothesis: asthma and chronic obstructive pulmonary disease are distinct diseases. *Am J Respir Crit Care Med*, **174**, 240-3.
- Barnes, PJ. (2006b). New therapies for asthma. *Trends Mol Med*, **12**, 515-20.
- Barnes, PJ. (2007). The problem of cough and development of novel antitussives. *Pulm Pharmacol Ther*, **20**, 416-22.

Barnes, PJ., Baraniuk, JN. and Belvisi, MG. (1991). Neuropeptides in the respiratory tract. *Am Rev Respir Dis*, **144**, 1187-98 and 1391-9.

Barnes, PJ., Chung, KF. and Page, CP. (1998). Inflammatory mediators of asthma: an update. *Pharmacol Rev*, **50**, 515-96.

Barsky, SH., Roth, MD., Kleeup, EC., Simmons, M. and Tashkin, DP. (1998). Histopathologic and molecular alterations in bronchial epithelium in habitual smokers of marijuana, cocaine, and/or tobacco. *J Natl Cancer Inst*, **90**, 1198-205.

Baumgartner, RA., Wills-Karp, M., Kaufman, MJ., Munakata, M. and Hirshman, C. (1990). Serotonin induces constriction and relaxation of the guinea-pig airway. *J Pharmacol Exp Ther*, **255**, 165-73.

Belvisi, MG. (2003). Airway sensory innervation as a target for novel therapies: an outdated concept? *Curr Opin Pharmacol*, **3**, 239-43.

Belvisi, MG., Hele, DJ. and Birrell, MA. (2004). New advances and potential therapies for the treatment of asthma. *Biodrugs*, **18**, 211-23.

Belvisi, MG., Patel, HJ., Freund-Michel, V., Hele, DJ., Crispino, D. and Birrell, MA. (2008). Inhibitory activity of the novel CB(2) receptor agonist, GW833972A, on guinea-pig and human sensory nerve function in the airways. *Br J Pharmacol*, **155**, 547-57.

Bentley, AM., Kay, AB. and Durham, SR. (1997). Human late asthmatic reactions. *Clin Exp Allergy*, **27**, 71-86.

Berry, MA., Hargadon, B., Shelley, M., Parker, D., Shaw, DE., Green, RH., Bradding, P., Brightling, CE., Wardlaw, AJ. and Pavord, ID. (2006). Evidence of a role of tumor necrosis factor  $\alpha$  in refractory asthma. *N Engl J Med*, **16**, 697-708.

Berry, MA., Parker, D., Neale, N., Woodman, L., Morgan, A., Monk, P., Bradding, P., Wardlaw, AJ., Pavord, ID. and Brightling, CE. (2004). Sputum and bronchial submucosal IL-13 expression in asthma and eosinophilic bronchitis. *J Allergy Clin Immunol*, **114**, 1106-9.

Bevan, S., Hothi, S., Hughes, G., James, IF., Rang, HP., Shah, K., Walpole, CSJ. and Yeats, JC. (1992). Capsazepine: a competitive antagonist of the sensory neurone excitant capsaicin. *Br J Pharmacol*, **107**, 544-52.

Bevan, S. and Szolcsányi, J. (1990). Sensory neuron-specific actions of capsaicin: mechanism and applications. *Trends Pharmacol Sci*, **11**, 330-3.

Bisogno, T., Hanuš, L., De Petrocellis, L., Tchilibon, S., Ponde, DE., Brandi, I., Moriello, AS., Davis, JB., Mechoulam, R. and Di Marzo., V. (2001). Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. *Br J Pharmacol*, **134**, 845-52.

Bisogno, T., Melck, D., Bobrov, MY., Gretskaya, NM., Bezuglov, VV., De Petrocellis, L., and Di Marzo., V. (2000). N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity *in vitro* and *in vivo*. *Biochem J*, **351**, 817-24.

Björck, T. and Dahlén, SE. (1993). Leukotrienes and histamine mediate IgE-dependent contractions of human bronchi: pharmacological evidence obtained with tissues from asthmatic and non-asthmatic subjects. *Pulm Pharmacol*, **6**, 87-96.

Bloemen, K., Verstraelen, S., Van Den Heuvel, R., Witters, H., Nelissen, I. and Schoeters, G. (2007). The allergic cascade: review of the most important molecules in the asthmatic lung. *Immunol Let*, **113**, 6-18.

Bonnans, C., Mainprice, B., Chanez, P., Bousuet, J. and Urbach, V. (2003). Lipoxin A<sub>4</sub> stimulates a cytosolic Ca<sup>2+</sup> increase in human bronchial epithelium. *J Biol Chem*, **278**, 10879-84.

Boyce, JA. (2003). Mast cells: Beyond IgE. *J Allergy Clin Immunol*, **111**, 24-32.

Bradding, P. (2003). The role of the mast cell in asthma: a reassessment. *Curr Opin Allergy Clin Immunol*, **3**, 45-50.

Bradding, P. (2005). Mast cells ion channels. *Chem Immunol Allergy*, **87**, 163-78.

Bradding, P. (2007). Mast cell regulation of airway smooth muscle function in asthma. *Eur Respir J*, **29**, 827-30.

Bradding, P. (2008). Novel approaches to the inhibition of mast cells in allergic disease. *Clin Exp Allergy*, **38**, 704-8.

Bradding, P. and Brightling, C. (2007). Mast cell infiltration of airway smooth muscle in asthma. *Respir Med*, **101**, 1045.

Bradding, P. and Holgate, ST. (1999). Immunopathology and human mast cell cytokines. *Crit Rev Oncol/Hematol*, **31**, 119-133.

Bradding, P., Walls, AF. and Holgate, ST. (2006). The role of mast cell in the pathophysiology of asthma. *J Allergy Clin Immunol*, **117**, 1277-84.

Breivogel, CS., Griffin, G., Di Marzo, V. and Martin, BR. (2001). Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. *Mol Pharmacol*, **60**, 155-63.

- Breschi, CM., Blandizzi, C., Fogli, S., Martinelli, C., Adinolfi, B., Calderone, V., Camici, M., Martinotti, E. and Nieri, P. (2007). *In vivo* adenosine A(2B) receptor desensitization in guinea-pig airway smooth muscle: implications for asthma. *Eur J Pharmacol*, **575**, 149-57.
- Brewster, CE., Howarth, PH., Djukanovic, R., Wilson, J., Holgate, ST. and Roche, WR. (1990). Myofibroblasts and subepithelial fibrosis in bronchial asthma. *Am J Respir Cell Mol Biol*, **3**, 507-11.
- Brightling, CE., Ammit, AJ., Kaur, D., Black, JL., Wardlaw, AJ., Hughes, JM. and Bradding, P. (2005). The CXCL10/CXCR3 axis mediates human lung mast cell migration to asthmatic airway smooth muscle. *Am J Respir Crit Care Med*, **171**, 1103-8.
- Brightling, CE., Bradding, P., Pavord, ID. and Wardlaw, AJ. (2003). New insights into the role of mast cell in asthma. *Clin Exp Allergy*, **33**, 550-6
- Brightling, CE., Bradding, P., Symon, FA., Holgate, ST., Wardlaw, AJ. and Pavord, ID. (2002). Mast-cell infiltration of airway smooth muscle in asthma. *N Engl J Med*, **346**, 1699-705.
- Brightling, CE., Symon, FA., Holgate, ST., Wardlaw, AJ., Pavord, ID. and Bradding, P. (2003). Interleukin-4 and -13 expression is co-localized to mast cells within the airway smooth muscle in asthma. *Clin Exp Allergy*, **33**, 1711-16.
- Brown, AJ. (2007). Novel cannabinoid receptors. *Br J Pharmacol*, **152**, 567-75.
- Brown, RA., Spina, D. and Page, CP. (2008). Adenosine receptors and asthma. *Br J Pharmacol*, **153**, S446-56.
- Brusselle, G., Kips, J., Joos, G., Bluethmann, H. and Pauwels, R. (1994). Allergen-induced airway inflammation and bronchial responsiveness in wild-type and IL-4-deficient mice. *Am J Respir Cell Mol Biol*, **12**, 254-9.
- Bueb, JL., Lambert, DM. and Tschihart, EJ. (2001). Receptor-independent effects of natural cannabinoids in rat peritoneal mast cells *in vitro*. *Biochim Biophys Acta*, **1538**, 252-9.
- Burnstock, G. (2004). Introduction: P2 receptors. *Curr Top Med Chem*, **4**, 793-803.
- Busse, WW. and Holgate, ST. (1995). Mast cells and basophils. In: *Astma & Rhinitis*. Boston: Blackwell Scientific Publications, 165-230.
- Butler, CA. and Heaney, LG. (2007). Neurogenic inflammation and asthma. *Inflamm Allergy Drug Targets*, **6**, 127-32.

Cabral, GA. and Staab, A. (2005). Effects on the immune system. *Springer-Verlag*, **168**, 385-423.

Calassi, MJ., Maruani, J., Barnouin, MC., Souilhac, J., Poncelet, M., Gueudet, C., Emonds-Alt, X., Soubrie, P., Breliere, JC. and Le Fur, G. (1993). Neuropharmacological characterization of SR140333, a non peptide antagonist of NK<sub>1</sub> receptors. *Neuropharmacol*, **33**, 167-79.

Calignano, A., Katona, I., Desarnaud, F., Giuffrida, A., La Rana, G., Mackie, K., Freund, TF. and Piomelli, D. (2000). Bidirectional control of airway responsiveness by endogenous cannabinoids. *Nature*, **408**, 96-101.

Canning, BJ. (1997). Potential role of tachykinins in inflammatory diseases. *J Allergy Clin Immunol*, **99**, 579-82.

Canning, BJ. (2006). Reflex regulation of airway smooth muscle tone. *J Appl Physiol*, **101**, 971-85.

Canning, BJ. and Fischer, A. (2001). Neural regulation of airway smooth muscle tone. *Resp Physiol*, **125**, 113-27.

Carrier, EJ., Auchampach, JA. and Hillard, CJ. (2006). Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. *Proc Natl Acad Sci USA*, **16**, 7895-900.

Casale, TB., Wood, D., Richerson, HB., Zehr, B., Zavala, D. and Hunninghake, GW. (1987). Direct evidence of a role for mast cells in the pathogenesis of antigen-induced bronchoconstriction. *J Clin Invest*, **80**, 1507-11.

Caterina, MJ., Schumacher, MA., Tominaga, M., Rosen, TA., Levine, JD. and Julius, D. (1997). The capsaicin receptor: a heat-activated ion channel in the pain pathway. *Nature*, **389**, 816-24.

Chahdi, A., Fraundorfer, PF. and Beaven, MA. (2000). Compound 48/80 activates mast cell phospholipase D via heterotrimeric GTP-binding proteins. *J Pharmacol Exp Ther*, **292**, 122-30.

Chand, N. and Sofia, RD. (1995). Histamine. In: Raeburn, D. and Giembycz, MA., editors. Airways Smooth Muscle: Neurotransmitters, Amines, Lipid Mediators and Signal Transduction. Berlin: Birkhäuser Verlag, 131-55.

Chanez, P., Wenzel, SE., Anderson, GP., Anto, JP., Bel, EH., Boulet, LP., Brightling, CE., Busse, WW., Castro, M., Dahlén, B., Dahlén, SE., Fabbri, LM., Holgate, ST., Humbert, M., Gaga, M., Joos, GF., Levy, B., Rabe, KF., Sterk, PJ., Wilson, SJ. and Vachier, I. (2007). Severe asthma in adults: what are the important questions? *J Allergy Clin Immunol*, **119**, 1337-48.

Chen, G., Zhou, D., Kim, JT., Wu, Z., Lee, LY. and Kang, BC. (1998). Contractile responses to allergen and cholinergic stimulation in bronchus and trachea of cockroach allergen-sensitized guinea-pigs. *Int Arch Allergy Immunol*, **116**, 132-9.

Chiba, Y. and Misawa, M. (1995). Inhibition of neutral endopeptidase increases airway responsiveness to ACh in non-sensitized normal rats. *J Appl Physiol*, **78**, 394-402.

Chiu, JC., Hsu, JY., Fu, LS., Chu, JJ. and Chi, CS. (2007). Comparison of the effects of two long-acting beta2-agonists on cytokine secretion by human airway epithelial cells. *J Microbiol Immunol Infect*, **40**, 388-94.

Chou, KJ., Tseng, LL., Cheng, JS., Wang, JL., Fang, HC., Lee, KC., Su, W., Law, YP. and Jan, CR. (2001). CP55,940 increases intracellular Ca<sup>2+</sup> levels in Madin-Darby canine kidney cells. *Life Sci*, **69**, 1541-8.

Chung, KF. (2005). Drugs to suppress cough. *Expert Opin Investig Drugs*, **14**, 19-27.

Clark, TT. and Udem, BJ. (2006). Airway sensory nerve mechanisms. *J Appl Physiol*, **27**, 1-39.

Cockcroft, DW. (1983). Mechanism of perennial allergic asthma. *Lancet*, **30**, 253-5.

Cockcroft, DW., Hargreave, FE., O'Byrne, PM. and Boulet, LP. (2007). Understanding of allergic asthma from allergen inhalation tests. *Can Respir J*, **14**, 414-8.

Coleman, RA., Humphrey, PP., Kennedy, I., Levy, GP. and Lumley, P. (1981). Comparison of the actions of U-46619, a prostaglandin H<sub>2</sub>-analogue, with those of prostaglandin H<sub>2</sub> and thromboxane A<sub>2</sub> on some isolated smooth muscle preparations. *Br J Pharmacol*, **73**, 773-8.

Communi, D., Paindavoine, P., Place, GA., Parmentier, M. and Boeynaems, JM. (1999). Expression of P2Y receptors in cell lines derived from the human lung. *Br J Pharmacol*, **127**, 562-8.

Corboz, MR., Fernandez, X., Rizzo, CA., Tozzi, S., Monahan, ME. and Hey, JA. (2003). Increased blocking activity of combined tachykinin NK<sub>1</sub>- and NK<sub>2</sub>-receptor antagonists on tachykinergic bronchomotor responses in the guinea-pig. *Auton Autacoid Pharmacol*, **23**, 79-93.

Corrigan, CJ. and Kay, AB. (1992). T cells and eosinophils in the pathogenesis of asthma. *Immunol Today*, **13**, 501-7.

Costa, B. (2007). On the pharmacological properties of Δ<sup>9</sup>-tetrahydrocannabinol (THC). *Chem Biodivers*, **4**, 1664-77.



Costa, B., Giagnoni, G., Franke, C., Trovato, AE. and Colleoni, M. (2004). Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the non-psychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation. *Br J Pharmacol*, **143**, 247-50.

Costa, B., Trovato, AE., Comelli, F., Giagnoni, G. and Colleoni, M. (2007). The non-psychoactive agent cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. *Eur J Pharmacol*, **556**, 75-83.

Coutts AA. and Izzo, AA. (2004). The gastrointestinal pharmacology of cannabinoids: an update. *Curr Opin Pharmacol*, **4**, 572-9.

Coutts AA. and Pertwee, RG. (1998). Evidence that cannabinoid-induced inhibition of electrically evoked contractions of the myenteric plexus-longitudinal muscle preparation of guinea-pig small intestine can be modulated by  $Ca^{2+}$  and cAMP. *Can J Physiol Pharmacol*, **76**, 340-6.

Cozens, AL., Yezzi, MJ., Kunzelmann, K., Ohri, T., Chin, L., Eng, K., Finkbeiner, WE., Widdicombe, JH. and Gruenert, DC. (1994). CFTR expression and chloride secretion in polarized immortal human bronchial epithelial cells. *Am J Respir Cell Mol Biol*, **10**, 38-47.

Craib, SJ., Ellington, HC., Pertwee, RG. and Ross, RA. (2001). A possible role of lipoxygenase in the activation of vanilloid receptors by anandamide in the guinea-pig bronchus. *Br J Pharmacol*, **134**, 30-7.

Cravatt, BF., Demarest, K., Patricelli, MP., Bracey, MH., Giang, DK., Martin, BR. and Lichtman, AH. (2001). Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. *Proc Natl Acad Sci USA*, **98**, 9371-6.

Cravatt, BF., Giang, DK., Mayfield, SP., Boger, DL., Lerner, RA. and Gilula, NB. (1996). Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. *Nature*, **384**, 83-7.

Croxford, JL. and Yamamura, T. (2005). Cannabinoids and the immune system: Potential for the treatment of inflammatory disease. *J Neuroimmunol*, **166**, 3-18.

Cui, YY., D'Agostino, B., Risse, PA., Marrocco, G., Naline, E., Zhang, Y., Chen, HZ., Finance, O., Rinaldi-Carmona, M., Rossi, F. and Advenier, C. (2007). Cannabinoid CB(2) receptor activation prevents bronchoconstriction and airway oedema in a model of gastro-oesophageal reflux. *Eur J Pharmacol*, **573**, 206-13.

Dahlén, SE., Hansson, G., Hedqvist, P., Björck, T., Granström, E. and Dahlén, B. (1983). Allergen challenge of lung tissue from asthmatics elicits bronchial contraction that correlates with the release of leukotrienes C<sub>4</sub>, D<sub>4</sub> and E<sub>4</sub>. *Proc Natl Acad Sci USA*, **80**, 1712-6.

Davies, BH., Radcliffe, S., Seaton, A. and Graham, JD. (1975). A trial of oral  $\Delta^1$ -(trans)-tetrahydrocannabinol in reversible airways obstruction. *Thorax*, **30**, 80-5.

De Filippis, D., D'Amico, A. and Iuvone, T. (2008a). Cannabinomimetic control of mast cell mediator release: new perspective in chronic inflammation. *J Neuroendocrin*, **20**, 20-5.

De Filippis, D., Iuvone, T., D'Amico, A., Esposito, G., Steardo, G., Herman, AG., Pelckmans, PA., De Winter, BY. and De Man, JG. (2008b). Effect of cannabidiol on sepsis-induced motility disturbances in mice: involvement of CB(1) receptors and fatty acid amide hydrolase. *Neurogastroenterol Motil*, **20**, 919-27.

De Filippis, D., Russo, A., D'Amico, A., Esposito, G., Concetta, P., Cinelli, M., Russo, G. and Iuvone, T. (2008c). Cannabinoids reduce granuloma-associated angiogenesis in rats by controlling transcription and expression of mast cell protease-5. *Br J Pharmacol*, **154**, 1672-9.

De Petrocellis, L., Harrison, S., Bisogno, T., Tognetto, M., Brandi, I., Smith, GD., Creminon, C., Davis, JB., Geppetti, P. and Di Marzo, V. (2001). The vanilloid receptor (VR1)-mediated effects of anandamide are potently enhanced by the cAMP-dependent protein kinase. *J Neurochem*, **77**, 1660-3.

De Swert, KO. and Joos, GF. (2006). Extending the understanding of sensory neuropeptides. *Eur J Pharmacol*, **533**, 171-81.

Del Giudice, E., Rinaldi, L., Passarotto, M., Facchinetti, F., D'Arrigo, A., Guitto, A., Carbonare, MD., Battistin, L. and Leon, A. (2007). Cannabidiol, unlike synthetic cannabinoids, triggers activation of RBL-2H3 mast cells. *J Leu Biol*, **81**, 1512-22.

Demuth, DG., Gkoumassi, E., Dröge, MJ., Dekkers, BG., Esselink, HJ., Van Ree, RM., Parsons, ME., Zaagsma, J., Molleman, A. and Nelemans, AS. (2005). Arachidonic acid mediates non-capacitative calcium entry by CB<sub>1</sub>-cannabinoid receptor activation in DDT<sub>1</sub> MF-2 smooth muscle cells. *J Cell Physiol*, **205**, 58-67.

Demuth, DG. and Molleman, A. (2006). Cannabinoid signalling. *Life Sci*, **78**, 549-63.

Devane, WA., Hanuš, L., Breuer, A., Pertwee, RG., Stevenson, LA., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A. and Mechoulam, R. (1992). Isolation and structure of brain constituent that binds to the cannabinoid receptor. *Science*, **258**, 1946-49.

- Diaz-Laviada, I. and Ruiz-Llorente, L. (2005). Signal transduction activated by cannabinoid receptors. *Mini Rev Med Chem*, **5**, 619-30.
- Di Marzo, V., Bisogno, T. and De Petrocellis, L. (2000). Endocannabinoids: new targets for drug development. *Curr Pharm Des*, **6**, 1361-80.
- Di Marzo, V. and De Petrocellis, L. (2006). Plant, synthetic and endogenous cannabinoids in medicine. *Annu Rev Med*, **57**, 553-74.
- Dixon, WE. and Brodie, TG. (1903). Contributions to the physiology of the lungs. Part I. The bronchial muscles, their innervation, and the action of drugs upon them. *J Physiol*, **29**, 97-173.
- Drmota, T., Greasly, P. and Goblewski, T. (2004). Screening assays for cannabinoid-ligand type modulators. Assignee: AstraZeneca. Patent WO2004074844.
- Dunford, PJ., O'Donnell, N., Riley, JP., Williams, KN., Karlsson, L., Thurmond, RL. (2006). The Histamine H<sub>4</sub> receptor mediates airway allergic inflammation by regulating the activation of CD4<sup>+</sup> T cells. *J Immunol*, **176**, 7062-70.
- Durham, SR. and Kay, AB. (1985). Eosinophils, bronchial hyper-reactivity and late-phase asthmatic reactions. *Clin Allergy*, **15**, 411-8.
- Earleywine, M. and Barnwell, SS. (2007). Decreased respiratory symptoms in cannabis users who vaporize. *Harm Reduct J*, 4-11.
- Ellis, J.L. and Udem, BJ. (1994a). Pharmacology of non-adrenergic, non-cholinergic nerves in airway smooth muscle. *Pulm Pharmacol*, **7**, 205-23.
- Ellis, JL. and Udem, BJ. (1994b). Inhibition by capsazepine of resiniferatoxin- and capsaicin-induced contractions of guinea-pig trachea. *J Pharmacol Exp Ther*, **268**, 85-9.
- Ellis, JL., Udem, BJ., Kays, JS., Ghanekar, SV., Barthlow, HG. and Buckner CK. (1993). Pharmacological examination of receptors mediating contractile responses to tachykinins in airways isolated from human, guinea-pig and hamster. *J Pharmacol Exp Ther*, **267**, 95-101.
- ElSohly, MA. and Slade, D. (2005). Chemical constituents of marijuana: The complex mixture of natural cannabinoids. *Life Sci*, **78**, 539-48.
- Emonds-Alt, X., Doutremepuich, JD., Heulme, M., Neliat, G., Santucci, V., Steinberg, R., Vilain, P., Bichon, D., Ducoux, JP., Proietto, V., Van Broeck, D., Soubrie, P., Le Fur, G. and Breliere, JC. (1993). *In vitro* and *in vivo* biological activities of SR140333, a novel potent non-peptide tachykinin NK<sub>1</sub> receptor antagonist. *Eur J Pharmacol*, **250**, 403-13.

Emonds-Alt, X., Vilain, P., Goulaouic, P., Proietto, V., Van Broeck, D., Advenier, C., Naline, E., Neliat, G., Le Fur, G. and Breliere, JC. (1992). A potent and selective non-peptide antagonist of the neurokinin A (NK<sub>2</sub>) receptor. *Life Sci*, **50**, 101-6.

Facci, L., Dal Toso, R., Romanello, S., Buriani, A., Skaper, SD. and Leon, A. (1995). Mast cells express peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. *Proc Natl Acad Sci USA*, **92**, 3376-80.

Fegley, D., Gaetani, S., Duranti, A., Tontini, A., Mor, M., Tarzia, G. and Piomelli, D. (2005). Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. *J Pharmacol Exp Ther*, **313**, 352-8.

Felder, CC., Dickanson-Chesterfield, AK. and Moore, SA. (2006). Cannabinoid biology. *Mol Interv*, **6**, 149-61.

Fernandez-Fernandez, JM., Nobles, M., Currid, A., Vazquez, E., Valverde, MA. (2002). Maxi K<sup>+</sup> channels mediate regulatory volume decrease response in a human bronchial epithelial cell line. *Am J Physiol Cell Physiol*, **283**, C1705-14.

Fimiani, C., Liberty, T., Aquirre, AJ., Amin, I., Ali, N. and Stefano, GB. (1999). Opiate, cannabinoid, and eicosanoid signaling converges on common intracellular pathways nitric oxide coupling. *Prost Lip Med*, **57**, 23-34.

Fligiel, S., Roth, MD., Kleerup, EC., Barsky, SH., Simmons, MS. and Tashkin, DP. (1997). Tracheobronchial histopathology in habitual smokers of cocaine, marijuana, and/or tobacco. *Chest*, **112**, 319-26.

Forbes, B. and Ehrhardt, C. (2005). Human respiratory epithelial cell culture for drug delivery applications. *Eur J Pharmac Biopharmac*, **60**, 193-205.

Forbes, B., Shah, A., Martin, GP. and Lansley, AB. (2003). The human bronchial epithelial cell line 16HBE14o- as a model system of the airways for studying drug transport. *Inter J Pharmac*, **257**, 161-7.

Fox, H. (2007). Anti-IgE in severe persistent allergic asthma. *Respirology*, **12**, 22-8.

Fox, AJ., Barnes, PJ., Venkatesan, P. and Belvisi, MG. (1997). Activation of large conductance potassium channels inhibits the afferent and efferent function of airway sensory nerves in the guinea-pig. *J Clin Invest*, **99**, 513-9.

Fride, E. and Mechoulam, R. (1993). Pharmacological activity of the cannabinoid agonist, anandamide, a brain constituent. *Eur J Pharmacol*, **231**, 313-4.

Frossard, N., Rhoed, KJ. and Barnes, PJ. (1989). Influence of epithelium on guinea-pig airway responses to tachykinins: role of endopeptidase and cyclooxygenase. *J Pharmacol Exp Ther*, **248**, 292-8.

Fujimura, M., Myou, S. Kamio, Y., Iwasa, K., Hashimoto, T. and Matsuda, T. (1999). Increased airway responsiveness to acetaldehyde in asthmatic subjects with alcohol-induced bronchoconstriction. *Eur Respir J*, **14**, 19-22.

Galiègue, S., Mary, S., Marchand, J., Dussossoy, D., Carrière, D., Carayon, P., Bouaboula, M., Shire, D., Le Fur, G. and Casellas, P. (1995). Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. *Eur J Biochem*, **232**, 54-61.

Geppetti, P., Materazzi, S. and Nicoletti, P. (2006). The transient receptor potential vanilloid 1: role in airway inflammation and disease. *Eur J Pharmacol*, **533**, 207-14.

Gilfillan, AM. and Tkaczyk, C. (2006). Integrated signalling pathway for mast-cell activation. *Nature Rev Immunol*, **6**, 218-30.

Gill, EW., Paton, WD. and Pertwee, RG. (1970). Preliminary experiments on the chemistry and pharmacology of cannabis. *Nature*, **228**, 134-6.

Gkoumassi, E., Dekkers, BGJ., Dröge, MJ., Elzinga, CRS., Schmidt, M., Meurs, H., Zaagsma, J. and Nelemans, SA. (2007). Virodhamine and CP55,940 modulate cAMP production and IL-8 release in human bronchial epithelial cells. *Br J Pharmacol*, **151**, 1041-8.

Godot, V., Arock, M., Garcia, G., Capel, F., Flys, C., Dy, M., Emilie, D. and Humbert, M. (2007). H<sub>4</sub> histamine receptor mediates optimal migration of mast cell precursors to CXCL12. *J Allergy Clin Immunol*, **120**, 827-34.

Goldie, RG., Paterson, JW. and Lulich KM. (1990). Adrenoceptors in airway smooth muscle. *Pharmac Ther*, **48**, 295-322.

Gong, H., Fligiel, S., Taskin, DP. and Barbers, RG. (1987). Tracheobronchial changes in habitual, heavy smokers of marijuana with and without tobacco. *Am Rev Respir Dis*, **136**, 142-9.

Gong, JP., Onaivi, ES., Ishiguro, H., Liu, QR., Tagliaferro, PA., Brusco, A. and Uhl, GR. (2006). Cannabinoid CB<sub>2</sub> receptors: immunohistochemical localization in rat brain. *Brain Res*, **1071**, 10-23.

Goutopoulos, A. and Makriyannis, A. (2002). From cannabis to cannabigerics: new therapeutic opportunities. *Pharmacol Ther*, **95**, 103-17.

- Graziano, FM. (1988). Mast cells and mast cell products. *Methods in Enzymology*, **162**, 501-22.
- Graham, JDP. (1986). The bronchodilator action of cannabinoids. In: Mechoulam, R. (Ed.), *Cannabinoids as therapeutic agents*. CRC Press, Boca Raton, FL, 147-58.
- Griffin, G., Fernando, SR., Ross, RA., McKay, NG., Ashford, MLJ., Shire, D., Huffman, JW., Yu, S., Lainton, JAH. and Pertwee, RG. (1997). Evidence for the presence of CB<sub>2</sub>-like cannabinoid receptors on peripheral nerve terminals. *Eur J Pharmacol*, **339**, 53-61.
- Grinspoon, L. (1969). Marihuana. *Scientific American*, **221**, 17-25.
- Groneberg, DA., Quarcoo, D., Frossard, N. and Fischer, A. (2004). Neurogenic mechanism in bronchial inflammatory diseases. *Allergy*, **59**, 1139-52.
- Groneberg, DA., Harrison, S., Dinh, QT., Geppetti, P. and Fischer, A. (2006). Tachykinins in the respiratory tract. *Current Drug Targets*, **7**, 1005-10.
- Grotenhermen, F. (2006). Cannabinoids and the endocannabinoid system. *Cannabinoids*, **1**, 10-4.
- Grundström, N., Andersson, RGG. and Wikberg JES. (1981). Pharmacological characterization of the autonomous innervation of the guinea-pig tracheobronchial smooth muscle. *Acta Pharmacol et Toxicol*, **49**, 150-7.
- Gunthorpe, MJ., Benham, CD., Randall, A. and Davis, JB. (2002). The diversity in the vanilloid (TRPV) receptor family of ion channels. *Trends Pharmacol Sci*, **23**, 183-91.
- Gunthorpe, MJ and Szallasi, A. (2008). Peripheral TRPV1 receptors as targets for drug development: new molecules and mechanism. *Curr Pharm Des*, **14**, 32-41.
- Gurish, MF. and Austen, KF. (2001). The diverse roles of mast cells. *J Exp Med*, **194**, F1-5.
- Hájos, N. and Freund, TF. (2002). Pharmacological separation of cannabinoid sensitive receptors on hippocampal excitatory and inhibitory fibers. *Neuropharmacol*, **43**, 503-10.
- Hájos, N., Ledent, C. and Freund, TF. (2001). Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. *Neuroscience*, **106**, 1-4.
- Hamilton, LM., Lozano, CT., Puddicombe, SM., Richter, A., Kimber, I., Dearman, RJ., Vrugt, B., Aalbers, R., Holgate, ST., Djukanovic, R., Wilson, SJ. and Davies, DE. (2003). The role of the epidermal growth factor receptor in sustaining neutrophil inflammation in severe asthma. *Clin Exp Allergy*, **33**, 233-40.

- Hanuš, L., Abu-Lafi, S., Fride, E., Breuer, A., Vogel, Z., Shalev, DE., et al. (2001). 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB<sub>1</sub> receptor. *Proc Natl Acad Sci USA*, **98**, 3662-65.
- Hartley, JP., Nogrady, SG. and Seaton, A. (1978). Bronchodilator effect of  $\Delta^1$ -tetrahydrocannabinol. *Br J Clin Pharm*, **5**, 523-5.
- Hashibe, M., Straif, K., Tashkin, DP., Morgenstern, H., Greenland S. and Zhang, ZF. (2005). Epidemiologic review of marijuana use and cancer risk. *Alcohol*, **35**, 265-75.
- Heavey, ML., Lau, W. and Pennefather, JN. (1997). Tachykinin receptors mediating non-cholinergic contraction of the guinea-pig isolated main bronchus in response to field stimulation. *Clin Exp Pharmacol Physiol*, **24**, 673-9.
- Herradón, E., Martín, MI. and López-Miranda, V. (2007). Characterization of the vasorelaxant mechanisms of the endocannabinoid anandamide in rat aorta. *Br J Pharmacol*, **152**, 699-708.
- Hiley, CR. and Kaup, SS. (2007). GPR55 and the vascular receptors for cannabinoids. *Br J Pharmacol*, **152**, 559-61.
- Hillard, CJ. and Jarrahian, A. (2003). Cellular accumulation of anandamide: consensus and controversy. *Br J Pharmacol*, **140**, 802-8.
- Hillard, CJ. and Jarrahian, A. (2005). Accumulation of anandamide: Evidence for cellular diversity. *Neuropharmacol*, **48**, 1072-8.
- Ho, WS. and Hiley, RC. (2004). Vasorelaxant activities of the putative endocannabinoid virodhamine in rat isolated small mesenteric artery. *J Pharmacy Pharmacol*, **56**, 869-75.
- Ho, WS. and Randall, MD. (2007). Endothelium-dependent metabolism by endocannabinoid hydrolases limits vasorelaxation to anandamide and 2-arachidonoylglycerol. *Br J Pharmacol*, **150**, 641-51.
- Holgate, ST. (2007a). Epithelium dysfunction in asthma. *J Allergy Clin Immunol*, **120**, 1233-44.
- Holgate, ST. (2007b). The epithelium takes centre stage in asthma and atopic dermatitis. *Trends Immunol*, **28**, 248-51.
- Holgate, ST. (2008). The airway epithelium is central to the pathogenesis of asthma. *Allerg Int*, **57**, 1-10.
- Holgate, ST., Djukanovic, R., Casale, T. and Bousquet, J. (2005). Anti-Immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy. *Clin Exp Allergy*, **35**, 408-16.

Holgate, ST. and Kay, AB. (1985). Mast cells, mediators and asthma. *Clin Allergy*, **15**, 221-34.

Holgate, ST. and Polosa, R. (2008). Treatment strategies for allergy and asthma. *Nat Rev Immunol*, 1-13.

Holt, PG. (2000). Key factors in the development of asthma: atopy. *Am J Respir Crit Care Med*, **161**, S172-5.

Howarth, PH., Babu, KS., Arshad, HS., Lau, L., Buckley, M., McConnell, W., Beckett, P., Ali, MA., Chauhan, A., Wilson, SJ., Reynolds, A., Davies, DE. and Holgate, ST. (2005). Tumor necrosis factor (TNF- $\alpha$ ) as a novel therapeutic target in symptomatic corticosteroid-dependent asthma. *Thorax*, **60**, 1012-8.

Howell, JB. and Altounyan, RE. (1967). A double-blind trial of disodium cromoglycate in the treatment of allergic bronchial asthma. *Lancet*, **2**, 539-42.

Howlett, AC. (2002). The cannabinoid receptors. *Prostaglandins Other Lipid Mediat*, **68-69**, 619-31.

Howlett, AC. (2005). Cannabinoid receptor signalling. In: Pertwee, RG. et al. *Cannabinoids*. Springer-Verlag Berlin Heidelberg **168**, 53-79.

Howlett, AC. and Mukhopadhyay, S. (2000). Cellular signal transduction by anandamide and 2-arachidonoylglycerol. *Chem Phys Lipids*, **108**, 53-70.

Howlett, AC., Barth, F., Bonner, TI., Cabral, G., Casellas, P., Devane, WA., Felder, CC., Herkenman, M., Mackie, K., Martin, BR., Mechoulam, R. and Pertwee, RG. (2002). International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. *Pharmacol Rev*, **54**, 161-202.

Huang, SM., Bisogno, T., Trevisani, M., Al-Hayani, A., De Petrocellis, L., Fezza, F. et al. (2002). An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR<sub>1</sub> receptors. *Proc Natl Acad Sci USA*, **99**, 8400-5.

Huffman, JW. (2005). CB<sub>2</sub> receptor ligands. *Mini Rev Med Chem*, **5**, 641-9.

Humbert, M., Gaga, M., Joos, GF., Levy, B., Rabe, KF., Sterk, PJ., Wilson, SJ. and Vachier, I. (2007). Severe asthma in adults: What are the important question? *J Allergy Clin Immunol*, **119**, 1337-48.

Humbles, AA., Lloyd, CM., McMillan, SJ., Friend, DS., Xanthou, G., McKenna, EE., Ghiran, S., Gerard, NP., Yu, C., Orkin, SH. and Gerard, C. (2004). A critical role for eosinophils in allergic airways remodeling. *Science*, **17**, 1776-9.



Hwang, SW., Cho, H., Kwak, J., Lee, SY., Kang, ChJ., Jung, J., Cho, S., Min, KH., Suh, YG., Kim, D. and Oh, U. (2000). Direct activation of capsaicin receptors by products of lipoxygenases: endogenous capsaicin-like substances. *Proc Natl Acad Sci USA*, **97**, 6155-60.

Ihenetu, K., Molleman, A., Parsons, M. and Whelan, CJ. (2003). Inhibition of interleukin-8 release in the human colonic epithelial cell line HT-29 by cannabinoids. *Eur J Pharmacol*, **458**, 207-15.

Ikawati, Z., Hayashi, M., Nose, M. and Maeyama, K. (2000). The lack of compound 48/80-induced contraction in isolated trachea of mast cell-deficient Ws/Ws rats *in vitro*: the role of connective tissue mast cells. *Eur J Pharmacol*, **402**, 297-306.

Ind, PW. (1994). Role of sympathetic nervous system and endogenous catecholamines in the regulation of the airways smooth muscle tone. In: Raeburn, D., Gymbiec, M. (Eds.), *Airways Smooth Muscle: Structure, Innervation and Neurotransmission*. Birkhauser Verlag, Basel, 29-41.

Iversen, L. (2005). Long-term effects of exposure to cannabis. *Curr Opin Pharmacol*, **5**, 69-72.

Izzo, AA. (2007). The cannabinoid CB<sub>2</sub> receptor: a good friend in the gut. *Neurogastroenterol Motil*, **19**, 704-8.

Jan, TR., Farraj, AK., Harkema, JR. and Kaminski, NE. (2003). Attenuation of the ovalbumin-induced allergic airway response by cannabinoid treatment in A/J mice. *Toxicol Appl Pharmacol*, **188**, 24-35.

Jan, TR., Su, ST., Wu, HY. and Liao, MH. (2007). Suppressive effects of cannabidiol on antigen-specific antibody production and functional activity of splenocytes in ovalbumin-sensitized BALB/c mice. *Int Immunopharmacol*, **7**, 773-80.

Jeffery, PK. and Haahtela, T. (2006). Allergic rhinitis and asthma: inflammation in a one-airway condition. *BMC Pulm Med*, **6**, S5.

Jia, Y. and Lee, LY. (2007). Role of TRPV receptors in respiratory diseases. *Bioch Biophys Acta*, **1772**, 915-27.

Jia, Y., McLeod, RL., Wang, X., Parra, LE., Egan, RW. and Hey, JA. (2002). Anandamide induces cough in conscious guinea-pigs through VR1 receptors. *Br J Pharmacol*, **137**, 831-6.

Johansson-Rydberg, IG., Andersson, RG. and Grundström, N. (1992). The modulatory effects of prostaglandins on both excitatory and inhibitory non-adrenergic non-cholinergic neurotransmission in guinea-pig airways. *Acta Physiol Scand*, **144**, 439-44.

Johns, DG., Behm, DJ., Walker, DJ., Ao, Z., Sahpland, EM., Daniels, DA., Riddick, M., Dowell, S., Staton, PC., Green, P., Shabon, U., Bao, W., Aiyar, N., Yue, TL., Brown, AJ., Morrison, AD. and Douglas, SA. (2007). The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. *Br J Pharmacol*, **152**, 825-31.

Jonsson, KO., Persson, E. and Fowler, CJ. (2006). The cannabinoid CB<sub>2</sub> receptor selective agonist JWH133 reduces mast cell oedema in response to compound 48/80 *in vivo* but not the release of  $\beta$ -hexosaminidase from skin slices *in vitro*. *Life Sci*, **78**, 598-606.

Joos, GF. and Pauwels, RA. (1993). The *in vivo* effects of tachykinins on airway mast cells of the rat. *Am Rev Respir Dis*, **148**, 922-6.

Joos, GF. and Pauwels, RA. (2001). Tachykinin receptor antagonists: potential in airways diseases. *Curr Opin Pharmacol*, **1**, 235-41.

Jung, M., Calassi, R., Maruani, J., Barnouin, MC., Souilhac, J., Poncelet, M., Gueudet, C., Emonds-Alt, X., Soubrie, P., Breliere, JC. and Le Fur, G. (1994). Neuropharmacological characterization of SR140333, a non-peptide antagonist of NK<sub>1</sub> receptors. *Neuropharmacol*, **33**, 167-79.

Kagaya, M., Lamb, J., Robbins, J., Page, CP. and Spina, D. (2002). Characterization of the anandamide induced depolarization of guinea-pig isolated vagus nerve. *Br J Pharmacol*, **137**, 39-48.

Kalant, H. (2001). Medicinal use of cannabis: History and current status. *Pain Res Manage*, **6**, 80-91.

Kalant, H. (2008). Smoked marijuana as medicine: not much future. *Clin Pharmacol Ther*, **83**, 517-9.

Kamei, J., Yoshikawa, Y. and Saitoh, A. (2006). Effect of N-arachidonoyl-(2-methyl-4-hydroxyphenyl) amine (VDM11), an anandamide transporter inhibitor, on capsaicin-induced cough in mice. *Cough*, **2**, 1-6.

Kano, M., Ohno-Shosaku, T., Maejima, T., Yoshida, T. and Hashimoto, K. (2004). Retrograde modulation of synaptic transmission mediated by endogenous cannabinoids. *Curr Neuropharmacol*, **2**, 49-57.

Karlsson, JA. (1994). Excitatory nonadrenergic, noncholinergic innervation of airways smooth muscle: role of peptides. In: Raeburn, D., Gymbiec, M. (Eds.), *Airways Smooth Muscle: Structure, Innervation and Neurotransmission*. Birkhauser Verlag, Basel, 103-42.

Karlsson, JA., Sant'Ambrogio, G. and Widdicombe J. (1988). Afferent neural pathways in cough and reflex bronchoconstriction. *J Appl Physiol*, **65**, 1007-23.

Kasri, NN., Parys, JB., Callewaert, G., Missiaen, L. and de Smedt, H. (2004). Calmodulin and calcium-release channels. *Biol Res*, **37**, 577-82.

Kasri, NN., Sienaert, I., Parys, JB., Callewaert, G., Missiaen, L., Jeromin, A. and De Smedt, H. (2003). A novel  $\text{Ca}^{2+}$ -induced  $\text{Ca}^{2+}$  release mechanism in A7r5 cells regulated by calmodulin-like proteins. *J Biol Chem*, **278**, 27548-55.

Kassel, O., De Blay, F., Duvernelle, C., Olgart, C., Israel-Biet, D., Krieger, P., Moreau, L., Muller, C., Pauli, G. and Frossard, N. (2001). Local increase in the number of mast cells and expression of nerve growth factor in the bronchus of asthmatic patients after repeated inhalation of allergen at low-dose. *Clin Exp Allergy*, **31**, 1432-40.

Kathuria, S., Gaetani, S., Fegley, D., Valino, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., La Rana, G., Calignano, A., Giustino, A., Tattoli, M., Palmery, M., Cuomo, V. and Piomelli, D. (2003). Modulation of anxiety through blockade of anandamide hydrolysis. *Nat Med*, **9**, 76-81.

Kawano, T., Matsuse, H., Kondo, Y., Machida, I., Saeki, S., Tomari, S., Mitsuta, K., Obase, Y., Fukushima, C., Shimoda, T. and Kohno, S. (2004). Acetaldehyde induces histamine release from human airway mast cells to cause bronchoconstriction. *Int Arch Allergy Immunol*, **134**, 233-9.

Keir, S., Boswell-Smith, V., Spina, D. and Page, C. (2006). Mechanism of adenosine-induced airways obstruction in allergic guinea pigs. *Br J Pharmacol*, **147**, 720-8.

Kellerman, DJ. (2002). P2Y2 receptor agonists: a new class of medication targeted at improved mucociliary clearance. *Chest*, **121**, 201-5.

Kerstan, D., Thomas, J., Nitschke, R. and Leipziger, J. (1999). Basolateral store-operated  $\text{Ca}^{2+}$ -entry in polarized human bronchial and colonic epithelial cells. *Cell Calcium*, **26**, 253-60.

Klein, TW. (2005). Cannabinoid-based drugs as anti-inflammatory therapeutics. *Nature*, **5**, 400-11.

Klein, TW., Newton, C., Larsen, K., Lu, L., Perkins, I., Nong, L. and Friedman, H. (2003). The cannabinoid system and immune modulation. *J Leu Biol*, **74**, 486-96.

Koibuchi, Y., Ichikawa, A., Nakagawa, M. and Tomita, K. (1985a). Histamine release induced from mast cells by active components of compound 48/80. *Eur J Pharmacol*, **115**, 163-70.

Koibuchi, Y., Ichikawa, A., Nakagawa, M. and Tomita, K. (1985b). Binding of active components of compound 48/80 to rat peritoneal mast cells. *Eur J Pharmacol*, **115**, 171-7.

Koslowsky, T., Hug, T., Ecke, D., Klein, P., Greger, R., Gruenert, DC. and Kunzelmann, K. (1994).  $\text{Ca}^{2+}$ - and swelling-induced activation of ion conductances in bronchial epithelial cells. *Pflügers Arch*, **428**, 597-603.

Kraft, M., Martin, RJ., Lazarus, SC., Fahy, JV., Boushey, HA., Lemanske, RF. and Szeffler, SJ. (2003). Airway tissue mast cells in persistent asthma: predictor of treatment failure when patients discontinue inhaled corticosteroids. *Chest*, **124**, 42-50.

Krumins, SA. and Broomfield, CA. (1992). Evidence of NK1 and NK2 tachykinin receptors and their involvement in histamine release in a murine mast cell line. *Neuropeptides*, **21**, 65-72.

Kummer, W., Fischer, A., Kurkowski, R. and Heym, C. (1992). The sensory and sympathetic innervation of guinea-pig lung and trachea as studied by retrograde neuronal tracing and double-labelling immunohistochemistry. *Neuroscience*, **49**, 715-37.

Kunzelmann, K., Kathöfer, S., Hipper, A., Gruenert, DC. and Greger, R. (1996). Culture-dependent expression of  $\text{Na}^+$  conductances in airway epithelial cells. *Pflügers Arch-Eur J Physiol*, **431**, 578-86.

Kunzelmann, K., Koslowsky, T., Hug, T., Gruenert, DC. and Greger, R. (1994). cAMP-dependent activation of ion conductances in bronchial epithelial cells. *Pflügers Arch*, **428**, 590-6.

Lai, YL. and Lin, TY. (2005). Mast cells in citric acid-induced cough of guinea-pigs. *Toxicol Appl Pharmacol*, **202**, 18-24.

Laloo, UG., Fox, AJ., Belvisi, MG., Chung, KF. and Barnes, PJ. (1995). Capsazepine inhibits cough induced by capsaicin and citric acid but not by hypertonic saline in guinea-pigs. *J Appl Physiol*, **79**, 1082-7.

Lambert, DM. and Di Marzo, V. (1999). The palmitoylethanolamide and oleamide enigmas: are these two fatty acid amides cannabimimetic? *Curr Med Chem*, **6**, 757-73.

Lambert, DM. and Fowler, CJ. (2005). The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications. *J Med Chem*, **48**, 5059-87.

Lau, AH. and Chow, SS. (2003). Effects of cannabinoid receptor agonists on immunologically induced histamine release from rat peritoneal mast cells. *Eur J Pharmacol*, **464**, 229-35.

Lauckner, JE., Jensen, JB., Chen, HY., Lu, HC., Hille, B. and Mackie, K. (2008). GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. *Proc Natl Acad Sci USA*, **105**, 2699-704.

Layman, JM. and Milton, AS. (1971). Some actions of  $\Delta^1$ -tetrahydrocannabinol and cannabidiol at cholinergic junctions. *Br J Pharmacol*, **41**, 379.

Lee, LY., Lin, YS., Gu, Q., Chung, E. and Ho CY. (2003). Functional morphology and physiological properties of bronchopulmonary C-fiber afferents. *The Anatomical Record Part A*, **270A**, 17-24.

Leung, KB., Flint, KC., Brostoff, J., Hudspith, BN., Johnson, NM., Lau, HY, Liu, WL. and Pearce, FL. (1988). Effects of sodium cromoglycate and nedocromil sodium on histamine secretion from human lung mast cells. *Thorax*, **43**, 756-61.

Lilly, CM., Hall, AE., Rodger, IW., Kobzik, L., Haley, KJ. and Drazen, JM. (1995). Substance P-induced histamine release in tracheally perfused guinea-pig lungs. *J Appl Physiol*, **78**, 1234-41.

Lindén, A. (1996). Increased interleukin-8 release by  $\beta$ -adrenoceptor activation in human transformed bronchial epithelial cells. *Br J Pharmacol*, **119**, 402-6.

Lindström, EG. and Andersson, RG. (1997). Neurokinin A-LI release after antigen challenge in guinea-pig bronchial tubes: influence of histamine and bradykinin. *Br J Pharmacol*, **122**, 417-22.

Lindström, EG., Grundström, N., Hammarström, S. and Andersson, RG. (1992). Relationship between histamine, lipoxigenase and cyclooxygenase products in antigen-induced contraction in guinea-pig tracheal tube preparation. *Pharmacol Toxicol*, **71**, 216-20.

Lodzki, M., Godin, B., Rakou, L., Mechoulam, R., Gallily, R. and Touitou, E. (2003). Cannabidiol-transdermal delivery and anti-inflammatory effect in a murine model. *J Control Release*, **93**, 377-87.

Lundberg, JM., Martling, CR. and Saria A. (1983). Substance P and capsaicin-induced contraction of human bronchi. *Acta Physiol Scand*, **119**, 49-53.

Lundberg, JM. and Saria A. (1982). Bronchial smooth muscle contraction induced by stimulation of capsaicin-sensitive sensory neurons. *Acta Physiol Scand*, **116**, 473-6.

Lutz, B. (2002). Molecular biology of cannabinoid receptors. *Prost Leukotr Essen Fatty Acids*, **66**, 123-42.

Maccarrone, M., Fiorucci, L., Erba, F., Bari, M., Finazzi-Agro, A. and Ascoli, F. (2000). Human mast cells take up and hydrolyze anandamide and do not express cannabinoid receptors. *FEBS Letters*, **468**, 176-80.

Mackie, K. (2008). Signalling via CNS cannabinoid receptors. *Mol Cell Endocrinol*, **286**, S60-5.

Mackie, K. and Stella, N. (2006). Cannabinoid receptors and endocannabinoids: evidence for new players. *The AAPS Journal*, **8**, E298-306.

Maggi, CA. and Meli, A. (1988). The sensory-efferent function of capsaicin-sensitive sensory neurons. *Gen Pharmac*, **19**, 1-43.

Maggi, CA., Patacchini, R., Perretti, F., Meini, S., Manzini, S., Santicioli, P., Del Bianco, E. and Meli, A. (1990). The effects of tiorphan and epithelium removal on contractions and tachykinin release produced by activation of capsaicin-sensitive afferents in the guinea-pig isolated bronchus. *Naunyn Schmiedeb Arch Pharmacol*, **341**, 74-9.

Maggi, CA., Patacchini, R., Quartara, L., Rovero, P. and Santicioli, P. (1991). Tachykinin receptors in the guinea-pig isolated bronchi. *Eur J Pharmacol*, **197**, 167-74.

Maier, KL., Wippermann, U. and Leuschel, L. (1999). Xenobiotic-metabolizing enzymes in the canine respiratory tract. *Inhal Toxicol*, **11**, 19-35.

Makriyannis, A., Mechoulam, R. and Piomelli, D. (2005). Therapeutic opportunities through modulation of the endocannabinoid system. *Neuropharmacol*, **48**, 1068-71.

Mapp, CE., Boniotti, A., Papi, A., Chitano, P., Coser, E., Di Stefano, A., Saetta, M., Ciaccia, A. and Fabbri, LM. (1993). The effect of compound 48/80 on contractions induced by toluene diisocyanate in isolated guinea-pig bronchus. *Eur J Pharmacol*, **248**, 67-73.

Martin, TJ. and Broadley, KJ. (2002). Contractile responses to adenosine, R-PIA and ovalbumin in passively sensitized guinea-pig isolated airways. *Br J Pharmacol*, **137**, 729-38.

Martini, FH. (1998). Epithelial tissue. In: *Fundamentals of anatomy and physiology*. Prentice Hall, USA, 109-19.

Massa, F., Storr, M. and Lutz, B. (2005). The endocannabinoid system in the physiology and pathophysiology of the gastrointestinal tract. *J Mol Med*, **83**, 944-54.

Massi, P., Valenti, M., Vaccani, A., Gasperi, V., Perletti, G., Marras, E., Fezza, F., Maccarone, M. and Parolaro, D. (2007). 5-Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid. *J Neurochem*, **104**, 1091-100.

Matsuda, LA., Lolait, SJ., Brownstein, MJ., Young, AC. and Bonner, TI. (1990). Structure of cannabinoid receptors and functional expression of the cloned cDNA. *Nature*, **346**, 561-4.

- Matsuse, H., Fukushima, C., Shimoda, T., Asai, S. and Kohno, S. (2007). Effects of acetaldehyde on human airway constriction and inflammation. *Novartis Found Symp*, **285**, 97-106.
- McFarland, MJ. and Barker, EL. (2004). Anandamide transport. *Pharmacol and Ther*, **104**, 117-35.
- McHugh, D., Tanner, C., Mechoulam, R., Pertwee, RG. and Ross, RA. (2008). Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: evidence for a site distinct from CB1 and CB2. *Mol Pharmacol*, **73**, 441-50.
- Mechoulam, R., Peters, M., Murillo-Rodriguez, E. and Hanuš, L. (2007). Cannabidiol-recent advances. *Chem Biodivers*, **4**, 1678-92.
- Mehra, R., Moore, BA., Crothers, K., Tetrault, J. and Fiellin, DA. (2006). The association between marijuana smoking and lung cancer. *Arch Intern Med*, **166**, 1359-67.
- Miggin, SM. and Kinsella, BT. (2002). Regulation of extracellular signal-regulated kinase cascades by alpha- and beta-isoforms of the human thromboxane A(2) receptor. *Mol Pharmacol*, **61**, 817-31.
- Molleman, A. (2003). Patch clamping: an introductory guide to patch clamp electrophysiology. Wiley, West Sussex, England.
- Mombouli, J., Schaeffer, G., Holzmann, S., Kostner, GM. and Graier, WF. (1999). Anandamide-induced mobilization of cytosolic Ca<sup>2+</sup> in endothelial cell. *Br J Pharmacol*, **126**, 1593-600.
- Montuschi, P., Sala, A., Dahlén, SE. and Folco, G. (2007). Pharmacological modulation of the leukotriene pathway in allergic airway disease. *Drug Discov Today*, **12**, 404-12.
- Moreira, FA., Kaiser, N., Monory, K. and Lutz, B. (2008). Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors. *Neuropharmacol*, **54**, 141-50.
- Morinelli, TA., Niewiarowski, S., Daniel, JL. and Smith, JB. (1987). Receptor-mediated effects of a PGH2 analogue (U 46619) on human platelets. *Am J Physiol*, **253**, H1035-43.
- Mormina, M., Thakur, S., Molleman, A., Whelan, CJ., Baydoun, A. (2006). Cannabinoid signalling in TNF- $\alpha$  induced IL-8 release. *Eur J Pharmacol*, **540**, 183-90.
- Mousli, M., Bueb, JL., Bronner, C., Rouot, B., and Landry, Y. (1990). G protein activation: a mode of action for cationic amphiphilic neuropeptides and venom peptides. *Tips*, **11**, 358-62.

Mousli, M., Bueb, JL., Rouot, B., Landry, Y. and Bronner, C. (1991). G-proteins as targets for non-immunological histamine releasers. *Agents and Actions*, **33**, 81-3.

Muccitelli, RM., Tucker, SS., Hay, DW., Torphy, TJ. and Wasserman, MA. (1987). Is the guinea-pig trachea a good *in vitro* model of human large and central airways? Comparison on leukotriene-, methacholine-, histamine- and antigen-induced contractions. *J Pharmacol Exp Ther*, **243**, 467-73.

Mukhopadhyay, S., Shim, JY., Assi, AA., Norford, D. and Howlett, AC. (2002). CB<sub>1</sub> cannabinoid receptor-G protein association: a possible mechanism for differential signaling. *Chem Phys Lipids*, **121**, 91-109.

Munro, S., Thomas, KL. and Abu-Shaar, M. (1993). Molecular characterization of a peripheral receptor for cannabinoids. *Nature*, **365**, 61-5.

Myers, A., Udem, B. and Kummer W. (1996). Anatomical and electrophysiological comparison of the sensory innervation of bronchial and tracheal parasympathetic ganglion neurons. *J Autonomic Nervous System*, **61**, 162-8.

Myou, S., Fujimura, M., Nishi, K., Watanabe, K., Matsuda, M., Ohka, T. and Matsuda, T. (1996). Effect of ethanol on airway calibre and non-specific bronchial responsiveness in patients with alcohol-induced asthma. *Allergy*, **51**, 52-5.

Nides, M. (2008). Update on pharmacologic options for smoking cessation treatment. *Am J Med*, **121**, S20-31.

Nieri, P., Martinotti, E., Testai, L., Adinolfi, B., Calderone, V. and Breschi, MC. (2003). R-(+)-methanandamide inhibits tracheal response to endogenously released acetylcholine via capsazepine-sensitive receptors. *Eur J Pharmacol*, **459**, 75-81.

Nieri, P., Martinotti, E., Testai, L., Martinelli, C. and Breschi, MC. (2003). Effects of cannabinoids on non-adrenergic non-cholinergic-mediated relaxation in guinea-pig trachea. *Eur J Pharmacol*, **475**, 115-8.

Norris, AA. and Alton, EW. (1996). Chloride transport and the action of sodium cromoglycate and nedocromil sodium in asthma. *Clin Exp Allergy*, **26**, 250-3.

Oka, S., Nakajima, K., Yamashita, A., Kishimoto, S. and Sugiura, T. (2007). Identification of GPR55 as a lysophosphatidylinositol receptor. *Biochem Biophys Res Commun*, **362**, 928-34.

Orzelek-O'Neil, RM., Goodman, FR. and Forney, RB. (1980a). Delta-9-tetrahydrocannabinol on isolated human bronchioles. *Arch Int Pharmacodyn*, **246**, 71-83.



- Orzelek-O'Neil, RM., Goodman, FR. and Forney, RB. (1980b). The effects of  $\Delta^9$ -tetrahydrocannabinol and nabilone on the isolated guinea-pig bronchus. *Toxicol Appl Pharmacol*, **54**, 493-50.
- O'Sullivan, SE., Kendall, DA. and Randall, MD. (2005). The effects of  $\Delta^9$ -tetrahydrocannabinol in rat mesenteric vasculature, and its interactions with the endocannabinoid anandamide. *Br J Pharmacol*, **145**, 514-26.
- Padilla, J., Daley, E., Chow, A., Robinson, K., Parthasarathi, K., McKenzie, AN., Tcherniq, T., Kurup, VP., Donaldson, DD. and Grunig, G. (2005). IL-13 regulates the immune response to inhaled antigens. *J Immunol*, **174**, 8097-105.
- Page, S., Ammit, AJ., Black, JL., Armour, CL. (2001). Human mast cell and airway smooth muscle cell interaction: implications for asthma. *Am J Physiol*, **281**, L1313-23.
- Palmer, SL., Khanolkar, AD. and Makriyannis, A. (2000). Natural and synthetic endocannabinoids and their structure-activity relationships. *Curr Pharm Des*, **6**, 1381-97.
- Patel, HJ., Birrell, MA., Crispino, N., Hele, DJ., Venkatesan, P., Barnes, PJ., Yacoub, MH. and Belvisi, MG. (2003). Inhibition of guinea-pig and human sensory nerve activity and the cough reflex in guinea-pigs by cannabinoid (CB<sub>2</sub>) receptor activation. *Br J Pharmacol*, **140**, 261-8.
- Pertwee, RG. (1997). Pharmacology of cannabinoid CB<sub>1</sub> and CB<sub>2</sub> receptors. *Pharmacol Ther*, **74**, 129-80.
- Pertwee, RG. (2001). Cannabinoid receptors and pain. *Prog Neurobiol*, **63**, 569-611.
- Pertwee, RG. (2004). Novel pharmacological targets for cannabinoids. *Curr Neuropharmacol*, **2**, 9-29.
- Pertwee, RG. (2005a). The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. *AAPS Journal*, **7**, E625-54.
- Pertwee, RG. (2005b). Inverse agonism and neutral antagonism at cannabinoid CB<sub>1</sub> receptors. *Life Sci*, **76**, 1307-24.
- Pertwee, RG. (2006a). Cannabinoid pharmacology: the first 66 years. *Br J Pharmacol*, **147**, S163-71.
- Pertwee, RG. (2006b). The pharmacology of cannabinoid receptors and their ligands: an overview. *Int J Obes*, **30**, S13-8.

Pertwee, RG. (2007a). The diverse CB<sub>1</sub> and CB<sub>2</sub> receptor pharmacology of three plant cannabinoids: Δ<sup>9</sup>-tetrahydrocannabinol, cannabidiol and Δ<sup>9</sup>-tetrahydrocannabivarin. *Br J Pharmacol*, [E-pub ahead of print].

Pertwee, RG. (2007b). GPR55: a new member of the cannabinoid receptor clan? *Br J Pharmacol*, **152**, 984-6.

Pertwee, RG. (2008). Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond. *Addict Biol*, **13**, 147-59.

Pertwee, RG., Fernando, SR., Nash, JE. and Coutts, AA. (1996). Further evidence for the presence of cannabinoid CB<sub>1</sub> receptors in guinea-pig small intestine. *Br J Pharmacol*, **118**, 2199-205.

Pertwee, RG. and Ross, RA. (2002). Cannabinoid receptors and their ligands. *Prost Leukot Ess Fatty Acids*, **66**, 101-21.

Pertwee, RG., Ross, RA., Craib, SJ. and Thomas, A. (2002). (-)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens. *Eur J Pharmacol*, **456**, 99-106.

Petitot, F., Donlan, M. and Michel, A. (2006). GPR55 as a new cannabinoid receptor: still a long way to prove it. *Chem Biol Drug Des*, **67**, 252-3.

Petitot, F., Jeantaud, B., Reibaud, M., Imperato, A. and Dubroeuq, MC. (1998). Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of Δ<sup>9</sup>-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. *Life Sci*, **63**, 1-6.

Pettipher, R. (2008). The roles of the prostaglandin D<sub>2</sub> receptors DP<sub>1</sub> and CRTH<sub>2</sub> in promoting allergic responses. *Br J Pharmacol*, **153**, S191-9

Piomelli, D. (2003). The molecular logic of endocannabinoid signalling. *Neurosci*, **4**, 873-84.

Porter, AC., Sauer, JM., Knierman, MD., Becker, GW., Berna, MJ., Bao, J., Nomikos, GG., Carrter, P., Bymaster, FP., Leese, AB. and Felder, CC. (2002). Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB<sub>1</sub> receptor. *J Pharmacol Exp Ther*, **301**, 1020-4.

Pulvirenti, N., Nasca, MR. and Micali, G. (2007). Topical adelmidrol 2% emulsion, a novel aliamide, in the treatment of mild atopic dermatitis in pediatric subjects: a pilot study. *Acta Dermatovenerol Croat*, **15**, 80-3.

Rakhshan, F., Day, TA., Blakely, RD. and Barker, EL. (2000). Carrier-mediated uptake of the endogenous cannabinoid anandamide in RBL-2H3 cells. *J Pharmacol Exp Ther*, **292**, 960-7.

Ralevic, V. (2003). Cannabinoid modulation of peripheral autonomic and sensory neurotransmission. *Eur J Pharmacol*, **472**, 1-21.

Rao, GK. and Kaminski, NE. (2006). Cannabinoid-mediated elevation of intracellular calcium: a structure-activity relationship. *J Pharmacol Exp Ther*, **317**, 820-9.

Re, G., Barbero, R., Miolo, A. and Di Marzo, V. (2007). Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: potential use in companion animals. *Vet J*, **173**, 21-30.

Rinaldi-Carmona, M., Barth, F., Heaulme, M., Alonso, R., Shire, D., Congy, C., Soubrie, P., Breliere, JC. and Le Fur, GL. (1995). Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. *Life Sci*, **56**, 1941-7.

Rinaldi-Carmona, M., Barth, F., Millan, J., Derocq, JM., Casellas, P., Congy, C., Oustric, D., Sarran, M., Bauaboula, M., Calandra, B., Portier, B., Shire, D., Breliere, JC. and Le Fur, GL. (1998). SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. *J Pharmacol Exp Ther*, **284**, 644-50.

Robinson, DS. (2004). The role of the mast cell in asthma: Induction of airway hyper-responsiveness by interaction with smooth muscle? *J Allergy Clin Immunol*, **114**, 58-65.

Robinson, DS., Bentley, AM., Hartnell, A., Kay, AB. and Durham, SR. (1993). Activated memory T helper cells in bronchoalveolar lavage fluid from patients with atopic asthma: relation to asthma symptoms, lung function, and bronchial responsiveness. *Thorax*, **48**, 26-32.

Rodríguez de Fonseca, FR., Del Arco, I., Bermudez-Silva, FJ., Bilbao, A., Cippitelli, A. and Navarro, M. (2005). The endocannabinoid system: physiology and pharmacology. *Alcohol Alcohol*, **40**, 2-14.

Roffel, AD. and Zaagsma, J. (1994). Acetylcholine. In: Raeburn, D., Gymbiec, M. (Eds.), *Airways Smooth Muscle: Neurotransmitters, Amines, Lipid Mediators and Signal Transduction*. Birkhauser Verlag, Basel, 81-130.

Rogers, DF. and Barnes, PJ. (2006). Treatment of airway mucus hypersecretion. *Ann Med*, **38**, 116-25.

- Roquet, A., Dahlén, B., Kumlin, M., Ihre, E., Anstrén, G., Binks, S. and Dahlén, SE. (1997). Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics. *Am J Respir Crit Care Med*, **155**, 1856-63.
- Ross, RA., Craib, SJ., Stevenson, LA., Pertwee, RG., Henderson, A., Toole, J. and Ellington, HC. (2002). Pharmacological characterization of the anandamide cyclooxygenase metabolite: prostaglandin E2 ethanolamide. *J Pharmacol Exp Ther*, **301**, 900-7.
- Rouzer, CA., Ford-Hutchinson, AW., Morton, HE. and Gillard, JW. (1990). MK886, a potent and specific leukotriene biosynthesis inhibitor blocks and reverses the membrane association of 5-lipoxygenase in ionophore-challenged leukocytes. *J Biol Chem*, **265**, 1436-42.
- Rumsfeld, JS. and Nallamothu, BK. (2008). The hope and fear of rimonabant. *JAMA*, **299**, 1601-2.
- Ryan, D., Drysdale, AJ., Pertwee, RG. and Platt, B. (2007). Interactions of cannabidiol with endocannabinoid signalling in hippocampal tissue. *Eur J Neurosci*, **25**, 2093-102.
- Ryberg, E., Larsson, N., Sjögren, S., Hjorth, S., Hermansson, NO., Leonova, J., Elebring, T., Nilsson, K., Drmota, T. and Greasley, PJ. (2007). The orphan receptor GPR55 is a novel cannabinoid receptor. *Br J Pharmacol*, **152**, 1092-101.
- Sacerdote, P., Martucci, C., Vaccani, A., Bariselli, F., Panerai, AE., Colombo, A., Parolaro, D. and Massi, P. (2005). The nonpsychoactive component of marijuana cannabidiol modulates chemotaxis and IL-10 and IL-12 production of murine macrophages both *in vivo* and *in vitro*. *J Neuroimmunol*, **159**, 97-105.
- Saito, Y., Sasaki, F., Tanaka, I., Sato, M., Okazawa, M., Sakakibara, H. and Suetsugu, S. (2001). Acute severe alcohol-induced bronchial asthma. *Intern Med*, **40**, 643-5.
- Saitoh, C., Kitada, C., Uchida, W., Chancellor, MB., De Groat, W. and Yoshimura, N. (2007). The differential contractile responses to capsaicin and anandamide in muscle strips isolated from the rat urinary bladder. *Eur J Pharmacol*, **570**, 182-7.
- Samson, MT., Howard, AS., Shimoda, LM., Huberson, MK., Stokes, AJ. and Turner, H. (2003). Differential roles of CB1 and CB2 cannabinoid receptors in mast cells. *J Immunol*, **170**, 4953-62.
- Sarafian, TA., Habib, N., Mao, JT., Tsu, IH., Yamamoto, ML., Hsu, E., Tashkin, DP. and Roth, MD. (2005). Gene expression changes in human small airway epithelial cells exposed to  $\Delta^9$ -tetrahydrocannabinol. *Toxicol Lett*, **158**, 95-107.

Sarafian, TA., Habib, N., Oldham, M., Seeram, N., Lee, RP., Lin, L., Tashkin, DP. and Roth, MD. (2006). Inhaled marijuana smoke disrupts mitochondrial energetics in pulmonary epithelial cells *in vivo*. *Am J Physiol Lung Cell Mol Physiol*, **290**, L1202-9.

Sarafian, TA., Kouyoumjian, S., Khoshaghideh, F., Tashkin, DP. and Roth, MD. (2003). Delta 9-tetrahydrocannabinol disrupts mitochondrial function and cell energetics. *Am J Physiol Lung Cell Mol Physiol*, **284**, L298-306.

Sawzdargo, M., Nguyen, T., Lee DK., Lynch, KR., Cheng, R., Heng HQ., George, SR. and O'Dowd, BF. (1999). Identification and cloning of three novel human G-protein-coupled receptor genes GPR52,  $\psi$ GPR53 and GPR55: GPR55 is extensively expressed in human brain. *Mol Brain Res*, **64**, 193-8.

Schoor, JV., Joos, GF. and Pauwels, RA. (2000). Indirect bronchial hyper-responsiveness in asthma: mechanism, pharmacology and implications for clinical research. *Eur Respir J*, **16**, 514-33.

Schwiebert, EM. and Zsembery, A. (2003). Extracellular ATP as a signaling molecule for epithelial cells. *Biochim Biophys Acta*, **1615**, 7-32.

Shapiro, BJ., Tashkin, MD., Vachon, L. (1977). Tetrahydrocannabinol as a bronchodilator. Why bother? *Chest*, **71**, 558-9.

Sherman-Gold, R. (1993). The Axon Guide for electrophysiology and biophysics laboratory techniques. Axon Instruments, Inc., Foster City, CA.

Shire, D., Carillon, C., Kaghad, M., Calandra, B., Rinaldi-Carmona, M., Le Fur, G., Caput, D. and Ferrara, P. (1995). An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. *J Biol Chem*, **270**, 3726-31.

Sienaert, I., Huyghe, S., Parys, JB., Malfait, M., Kunzelmann, K., De Smedt, H., Verleden, GM. and Missiaen, L. (1998). ATP-induced  $Ca^{2+}$  signals in bronchial epithelial cells. *Pflügers Arch-Eur J Physiol*, **436**, 40-8.

Singer, CA., Salinthonne, S., Baker, KJ. and Gerthoffer, WT. (2004). Synthesis of immune modulators by smooth muscles. *Bioessays*, **26**, 646-55.

Singh, J. and Kraft, M. (2008). Anti-IgE and other antibody targets in asthma. *Handb Exp Pharmacol*, **181**, 257-88.

Sisson, JH. (2007). Alcohol and airways function in health and disease. *Alcohol*, **41**, 293-307.

Small-Howard, AL., Shimoda, LM., Adra, CN. and Turner, H. (2005). Anti-inflammatory potential of  $CB_1$ -mediated cAMP elevation in mast cells. *Biochem J*, **388**, 465-73.

Smart, D., Gunthorpe, MJ., Jerman, JC., Nesir, S., Gray, J., Muir, AI., Chambers, JK., Randall, AD. and Davis, JB. (2000). The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). *Br J Pharmacol*, **129**, 227-30.

Smith, N. and Broadley, KJ. (2007). Optimisation of the sensitisation conditions for an ovalbumin challenge model of asthma. *Int Immunopharmacol*, **7**, 183-90.

Smith, N. and Johnson, FJ. (2005). Early- and late-phase bronchoconstriction, airway hyper-reactivity and cell influx into lungs, after 5'-adenosine monophosphate inhalation: comparison with ovalbumin. *Clin Exp Allergy*, **35**, 522-30.

Spicuzza, L., Di Maria, G. and Polosa, R. (2006). Adenosine in the airways: implications and applications. *Eur J Pharmacol*, **533**, 77-88.

Spicuzza, L., Haddad, EB., Birrell, M., Ling, A., Clarke, D., Venkatesan, P., Barnes, PJ. and Belvisi, MG. (2000). Characterization of the effects of cannabinoids on guinea-pig tracheal smooth muscle tone: role in the modulation of acetylcholine release from parasympathetic nerves. *Br J Pharmacol*, **130**, 1720-6.

Spina, D. (1996). Airway sensory nerves: a burning issue in asthma? *Thorax*, **51**, 335-7.

Srivastava, MD., Srivastava, BI. and Brouhard, B. (1998).  $\Delta^9$  Tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells. *Immunopharmacol*, **40**, 179-85.

Staton, PC., Hatcher, JP., Walker, DJ., Morrison, AD., Shapland, EM., Hughes, JP., Chong, E., Mander, PK., Green, PJ., Billinton, A., Fulleylove, M., Lancaster, HC., Smith, JC., Bailey, LT., Wise, A., Brown, AJ., Richardson, JC., Chessell, IP. (2008). The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain. *Pain*, **139**, 225-36.

Stebbins, KJ., Carr, MJ., Pedapati, EV. and Ellis, JL. (2003). Effect of olvanil on the afferent function of capsaicin-sensitive C-fibers in guinea-pig airways. *Eur J Pharmacol*, **471**, 205-11.

Steffens, M., Zentner, J., Honegger, J. and Feuerstein, TJ. (2005). Binding affinity and agonist activity of putative endogenous cannabinoids at the human neocortical CB<sub>1</sub> receptor. *Biochem Pharmacol*, **69**, 169-78.

Stengel, PW., Rippy, MK., Cockerham, SL., Devane, WA. and Silbaugh, SA. (1998). Pulmonary actions of anandamide, an endogenous cannabinoid receptor agonist, in guinea pigs. *Eur J Pharmacol*, **355**, 57-66.

Straiker, A. and Mackie, K. (2006). Cannabinoids, electrophysiology, and retrograde messengers: challenges for the next 5 years. *AAPS Journal*, **8**, E272-6.

- Sugiura, T., Oka, S., Gokoh, M., Kishimoto, S. and Waku, K. (2004). New perspectives in the studies on endocannabinoid and cannabis: 2-arachidonoylglycerol as a possible novel mediator of inflammation. *J Pharmacol Sci*, **96**, 367-75.
- Sugiura, T. and Waku, K. (2000). 2-Arachidonoyl glycerol and the cannabinoid receptors. *Chem Phys Lipids*, **108**, 89-106.
- Szallasi, A. and Blumberg, PM. (1999). Vanilloid (capsaicin) receptors and mechanisms. *Pharmacol Rev*, **51**, 159-211.
- Tarzia, G., Duranti, A., Tontini, A., Piersanti, G., Mor, M., Rivara, S., Plazzi, PV., Park, C., Kathuria, S. and Piomelli, D. (2003). Design, synthesis, and structure-activity relationships of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors. *J Med Chem*, **46**, 2352-60.
- Tashkin, DP., Baldwin, GC., Sarafian, T., Dubinett, S., and Roth, MD. (2002). Respiratory and immunologic consequences of marijuana smoking. *J Clin Pharmacol*, **42**, S71-81.
- Tashkin, DP., Calvarese, BM., Simmons, MS. and Shapiro, BJ. (1980). Respiratory status of seventy-four habitual marijuana smokers. *Chest*, **78**, 699-706.
- Tashkin, DP., Reiss, S., Shapiro, BJ., Calvarese, B., Olsen, JL. and Lodge, JW. (1977). Bronchial effects of aerosolized  $\Delta^9$ -tetrahydrocannabinol in healthy and asthmatic subjects. *Am Rev Respir Dis*, **115**, 57-65.
- Tashkin, DP., Shapiro, BJ., Lee, YE. and Harper, CE. (1975). Effects of smoked marijuana in experimentally induced asthma. *Am Rev Respir Dis*, **112**, 377-86.
- Taylor, SM., Paré, PD. and Schellenberg, RR. (1984). Cholinergic and nonadrenergic mechanisms in human and guinea-pig airways. *J Appl Physiol*, 958-65.
- Taylor, AL., Schwiebert, LM., Smith, JJ., King, C., Jones, JR., Sorscher, EJ. and Schwiebert, EM. (1999). Epithelial P2X purinergic receptor channel expression and function. *J Clin Invest*, **104**, 875-84.
- Thakur, GA., Spyros, NP. and Makriyannis, A. (2005). CB<sub>1</sub> cannabinoid receptor ligands. *Mini Rev Med Chem*, **5**, 631-40.
- Thomas, A., Baillie, GL., Phillips, AM., Razdan, RK., Ross, RA. and Pertwee, RG. (2007). Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists *in vitro*. *Br J Pharmacol*, **150**, 613-23.
- Tomioka, M., Ida, S., Shindoh, Y., Ishihara, T. and Takishima, T. (1984). Mast cells in bronchoalveolar lumen of patients with bronchial asthma. *Am Rev Respir Dis*, **129**, 1000-5.

Trevethick, M. (2007). The potential to treat lung inflammation with ligands acting at the adenosine A<sub>2A</sub> receptor- the promise and the issue. In: Cutting Edge Concepts in Lung Pharmacology. British Pharmacological Society: Crieff, Perthshire, Scotland, 22.

Trevethick, MA., Mantell, SJ., Stuart, EF., Barnard, A., Wright, KN. and Yeadon, M.. (2008). Treating lung inflammation with agonists of the adenosine A<sub>2A</sub> receptor: promises, problems and potential solutions. *Br J Pharmacol*, **155**, 463-74.

Trevisani, M., Gazzieri, D., Benvenuti, F., Campi, F., Dinh, QT., Groneberg, DA., Rigoni, M., Emonds-Alt, X., Creminon, C., Fischer, A., Geppetti, P. and Harrison, S. (2004). Ethanol causes inflammation in the airways by a neurogenic and TRPV1-dependent mechanism. *J Pharmacol Exp Ther*, **309**, 1167-73.

Trevisani, M., Smart, D., Gunthorpe, MJ., Tognetto, M., Barbieri, M., Campi, B., Amadesi, S., Gray, J., Jerman, JC., Brough, SJ., Owen, D., Smith, GD., Randall, AD., Harrison, S., Bianchi, A., Davis, JB. and Geppetti, P. (2002). Ethanol elicits and potentiates nociceptor responses via the vanilloid receptor-1. *Nature Neurosci*, **5**, 546-51.

Tucker, RC., Kagaya, M., Page, CP. and Spina, D. (2001). The endogenous cannabinoid agonist, anandamide stimulates sensory nerves in guinea-pig airways. *Br J Pharmacol*, **132**, 1127-35.

Türker, RK., Kaymakcalan, S. and Ercan, ZS. (1975). Antihistaminic action of (-)-trans-delta-9-tetrahydrocannabinol. *Arch Int Pharmacodyn*, **214**, 254-62.

Undem, BJ. and Carr, MJ. (2002). The role of nerves in asthma. *Curr Allergy Asthma Reports*, **2**, 159-65.

Vachon, L., Fitzgerald, MX., Solliday, NH., Gould, IA. and Gaensler, EA. (1973). Single-dose effect of marijuana smoke: bronchial dynamics and respiratory-center sensitivity in normal subjects. *N Engl J Med*, **288**, 985-9.

Vandevoorde, S. and Lambert, DM. (2005). Focus on the three key enzymes hydrolysing endocannabinoids as new drug targets. *Curr Pharml Des*, **11**, 2647-68.

Vannacci, A., Giannini, L., Passani, MB., Felice, AD., Pierpaoli, S., Zagli, G., Fantappie, O., Mazzanti, R., Masini, E. and Mannaioni, PF. (2004). The endocannabinoid 2-arachidonylglycerol decreases the immunological activation of guinea-pig mast cells: involvement of nitric oxide and eicosanoids. *J Pharmacol Exp Ther*, **311**, 256-64.

Vannacci, A., Passani, MB., Pierpaoli, S., Giannini, L., Mannaioni, PF. and Masini, E. (2003). Nitric oxide modulates the inhibitory effect of cannabinoids on the immunological activation of guinea-pig mast cells. *Inflamm Res*, **52**, S07-8.



Vannacci, A., Zagli, G., Marzocca, S., Pierpaoli, S., Passani, MB., Mannaioni, PF. and Masini, E. (2002). Down-regulation by cannabinoids of the immunological activation of human basophils and guinea-pig mast cells. *Inflamm Res*, **51**, S09-10.

Van der Stelt, M. and Di Marzo, V. (2004). Metabolic fate of endocannabinoids. *Curr Neuropharmacol*, **2**, 37-48.

Van Gaal, LF., Rissanen, AM., Scheen, AJ., Ziegler, O. and Rössner, S. (2005). Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. *Lancet*, **365**, 1389-97

Van Ganse, E., Kaufman, L., Derde, MP., Yernault, JC., Delaunoy, L., Vincken, W. (1997). Effects of antihistamines in adult asthma: a meta-analysis of clinical trials. *Eur Respir J*, **10**, 2216-24.

Van Sickle, MD., Duncan, M., Kingsley, PJ., Mouihate, A., Urbani, P., Mackie, K., Stella, N., Makriyannis, A., Piomelli, D., Davison, JS., Marnett, LJ., Di Marzo, V., Pittman, QJ., Patel, KD. and Sharkey, KA. (2005). Identification and functional characterization of brainstem cannabinoid CB<sub>2</sub> receptors. *Science*, **310**, 329-32.

Vizi, ES., Katona, I. and Freund, TF. (2001). Evidence for presynaptic cannabinoid CB<sub>1</sub> receptor-mediated inhibition of noradrenaline release in the guinea-pig lung. *Eur J Pharmacol*, **431**, 237-44.

Walsh, DE., Harvey, BJ. and Urbach, V. (2000). CFTR regulation of intracellular calcium in normal and cystic fibrosis human airway epithelia. *J Membrane Biol*, **177**, 209-19.

Wan, H., Winton, HL., Soeller, C., Stewart, GA., Thompson, PJ., Gruenert, DC., Cannell, MB., Garrod, DR. and Robinson, C. (2000). Tight junction properties of the immortalized human bronchial epithelial cell lines Calu-3 and 16HBE14o-. *Eur Respir J*, **15**, 1058-68.

Wardlaw, AJ., Dunnette, S., Gleich, GJ., Collins, JV. and Kay, AB. (1988). Eosinophils and mast cells in bronchialalveolar lavage in subjects with mild asthma. *Am Rev Respir Dis*, **137**, 62-9.

Ware, MA. (2008). Marijuana as medicine: does it have a future? *Clin Pharmacol Ther*, **83**, 515-7

Watanabe, N., Horie, S., Michael, GJ., Spina, D., Page, CP. and Priestley, JV. (2005). Immunohistochemical localization of vanilloid receptor subtype 1 (TRPV<sub>1</sub>) in the guinea-pig respiratory system. *Pulm Pharmacol Ther*, **18**, 187-97.

Watanabe, N., Kayano, Y., Matsunaga, T., Yamamoto, I. and Yoshimura, H. (1996). Inhibition of anandamide amidase activity in mouse brain microsomes by cannabinoids. *Biol Pharm Bull*, **19**, 1109-11.

Watson, N., Maclagan, J. and Barnes, PJ. (1993). Endogenous tachykinins facilitate transmission through parasympathetic ganglia in guinea-pig trachea. *Br J Pharmacol*, **109**, 751-9.

Weiss, L., Zeira, M., Reich, S., Har-Noy, M., Mechoulam, R., Slavin, S. and Gallily, R. (2006). Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. *Autoimmunity*, **39**, 143-51.

Wells, E., Jackson, CG., Harper, ST., Mann, R. and Eady, RP. (1986). Characterization of primate bronchoalveolar mast cells. II. Inhibition of histamine, LTC<sub>4</sub>, and PGD<sub>2</sub> release from primate bronchoalveolar mast cells and a comparison with rat peritoneal mast cells. *J Immunol*, **137**, 3941-5.

Welsh, MJ. and Fick, RB. (1987). Cystic fibrosis. *J Clin Investig*, **80**, 1523-6.

Welsh, MJ and Liedtke, CM. (1986). Chloride and potassium channels in cystic fibrosis airway epithelia. *Nature*, **322**, 467-70.

Whelan, CJ. (2009). Evidence that 13-14 di-hydro, 15-keto prostaglandin D<sub>2</sub>-induced airway eosinophilia in guinea-pigs is independent of interleukin-5. *Inflamm Res*, **58**, 103-8.

Wilkinson, JD., Kendall, DA. and Ralevic, V. (2007).  $\Delta^9$ -Tetrahydrocannabinol inhibits electrically-evoked CGRP release and capsaicin-sensitive sensory neurogenic vasodilation in the rat mesenteric arterial bed. *Br J Pharmacol*, **152**, 709-16.

Williams, CM., and Galli, SJ. (2000). The diverse potential effector and immunoregulatory roles of mast cells in allergic disease. *J Allergy Clin Immunol*, **105**, 847-59.

Wilson, CN. (2007). Adenosine- which receptor to antagonize. In: Cutting Edge Concepts in Lung Pharmacology. British Pharmacological Society: Crieff, Perthshire, Scotland, 25.

Wolber, C., Baur, F. and Fozard, JR. (2004). Interaction between adenosine and allergen or compound 48/80 on lung parenchymal strips from actively sensitized Brown Norway rats. *Eur J Pharmacol*, **498**, 227-32.

Wolff, SC., Qi, AD., Harden, TK. and Nicholas, RA. (2005). Polarized expression of human P<sub>2</sub>Y receptors in epithelial cells from kidney, lung, and colon. *Am J Physiol Cell Physiol*, **288**, C624-32.

Woodman, L., Sutcliffe, A., Kaur, D., Berry, M., Bradding, P., Pavord, ID. and Brightling, CE. (2006). Chemokine concentrations and mast cell chemotactic activity in BAL fluid of patients with eosinophilic bronchitis and asthma, and in normal control subjects. *Chest*, **130**, 371-8.

Woolcock, AJ. (1995). Treatment of asthma. In: Busse, WW. and Holgate ST., editors. *Astma & Rhinitis*. Boston: Blackwell Scientific Publications, 1364-79.

Wright, S. (2007). Cannabinoid- based medicines for neurological disorders- clinical evidence. *Mol Neurobiol*, **36**, 129-36.

Wright, SM., Dikkers, MA. and Aronne, LJ. (2008). Rimonabant: new data and emerging experience. *Curr Atheroscler Rep*, **10**, 71-8.

Wright, K., Rooney, N., Feeney, M., Tate, J., Robertson, D., Welham, M. and Ward, S. (2005). Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. *Gastroenterol*, **129**, 437-53.

Yoshihara, S., Morimoto, H., Yamada, Y., Abe, T. and Arisaka, O. (2004). Cannabinoid receptor agonists inhibit sensory nerve activation in guinea-pig airways. *Am J Respir Crit Care Med*, **170**, 941-6.

Yoshihara, S., Morimoto, H., Ohori, M., Yamada, Y., Abe, T. and Arisaka, O. (2005). Endogenous cannabinoid receptor agonists inhibit neurogenic inflammation in guinea-pig airways. *Int Arch Allergy Immunol*, **138**, 80-7.

Zsembery, A., Boyces, AT., Liang, L., Peti-Peterdi, J., Bell, PD. and Schwiebert, EM. (2003). Sustained calcium entry through P2X nucleotide receptor channels in human airway epithelial cells. *J Biol Chem*, **278**, 13398-408.

Zimmerman, S., Zimmerman, AM., Cameron, IL. and Laurence, HL. (1977).  $\Delta^1$ -Tetrahydrocannabinol, Cannabidiol and Cannabinol effects on the immune response of mice. *Pharmacology*, **15**, 10-23.

Zoratti, C., Korgun, D., Osibow, K., Malli, R. and Graier, WF. (2003). Anandamide initiates  $Ca^{2+}$  signalling via  $CB_2$  receptor linked to phospholipase C in calf pulmonary endothelial cells. *Br J Pharmacol*, **140**, 1351-62.

Zygmunt, PM., Andersson, DA. and Högestätt, ED. (2002).  $\Delta^9$ -Tetrahydrocannabinol and cannabinol activate capsaicin-sensitive sensory nerves via a  $CB_1$  and  $CB_2$  cannabinoid receptor-independent mechanism. *J Neurosci*, **22**, 4720-7.

Zygmunt, PM., Petersson, J., Andersson, DA., Chuang, HH., Sorgard, M., Di Marzo, V., Julius, D. and Högestätt, ED. (1999). Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. *Nature*, **400**, 452-7.